Vitiligo is common in the hereditary disorder autoimmune polyendocrine syndrome type I (APS I). Patients with APS I are known to have high-titre autoantibodies directed against various tissue-specific antigens. Using sera from APS I patients for immunoscreening of a cDNA-library from human scalp, we identified the transcription factors SOX9 and SOX10 as novel autoantigens related to this syndrome. Immunoreactivity against SOX9 was found in 14 (15%) and against SOX10 in 20 (22%) out of the 91 APS I sera studied. All patients reacting with SOX9 displayed reactivity against SOX10, suggesting shared epitopes. Among the 19 patients with vitiligo 12 (63%) were positive for SOX10 (p<0.0001). Furthermore, three out of 93 sera from patients with vitiligo unrelated to APS I showed strong reactivity against SOX10, which may indicate a more general role of SOX10 as an autoantigen in vitiligo.
Introduction
The autosomal recessively inherited disease autoimmune polyendocrine syndrome type I (APS I), also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is characterised by organ-specific autoimmunity, mucocutaneous candidiasis and ectodermal manifestations (1) . The gene responsible for the syndrome has recently been identified and named autoimmune regulator (AIRE), coding for a protein with the characteristics of a transcription factor (2, 3) .
Two of the classical triad of mucocutaneous candidiasis, hypo-parathyroidism and adrenocortical insufficiency are required for the clinical diagnosis (4) . Other severe manifestations such as autoimmune chronic active hepatitis, gonadal failure, malabsorption, and insulin-dependent diabetes mellitus (IDDM) may also affect the patients. Furthermore, ectodermal manifestations such as vitiligo, alopecia, and nail and enamel dystrophy are frequently seen (1, 5) . High-titer autoantibodies against affected tissues is a hallmark of APS I.
The antigenic structures identified have been shown to be important, tissue-specific keyenzymes (6-13), some of which seems to act as autoantigens also in other more common autoimmune diseases (14) .
Vitiligo is a depigmenting skin disorder with a prevalence in the general population of about 1% (15) . The etiology is largely unknown, but autoimmune mechanisms are thought to be involved. It is associated with various autoimmune disorders (16) such as IDDM (17) , thyroid disease (18, 19) , pernicious anaemia (20, 21) and is often a component in autoimmune polyendocrinopathies (4) including APS I (1, 5) . Autoantibodies against melanocytes have been reported in patients with vitiligo unrelated to APS I (22, 23) , but the major autoantigens in vitiligo are yet to be identified. The possible roles of tyrosinase, tyrosinase-related protein-1 (TPR-1) and tyrosinase-related protein-2 (TPR-2), key enzymes in the synthesis of melanin, as well as the melanosomal matrix glycoprotein, pmel17 (24) , as melanocyte autoantigens remain largely unresolved. Some studies report frequent immunoreactivity against these proteins in patients with vitiligo (25) , whilst other studies show only a low frequency of immunoreactivity (26) . In the majority of the patients studied with vitiligo and APS I complement-fixing antibodies directed against melanin-producing cells were identified (27, 28) . This immunoreactivity was not demonstrated in patients with isolated vitiligo or vitiligo associated with other autoimmune disorders (28) and can be found in patients with APS I many years before the development of vitiligo (29) .
Sera from patients with APS I are known to contain high-titre autoantibodies which makes APS I a suitable disease model for identification of autoantigens. We recently demonstrated the presence of immunoreactivity against melanocyte nuclei in both hair follicles and epidermis in APS I patients (30) . Since vitiligo is common in APS I, affecting 8-15% of the patients (1, 5) , this study aims at further characterisation of the antigenic structures related to this manifestation.
Experimental procedures
Sera. Samples from 91 APS I patients and 93 patients with vitiligo unrelated to APS I were tested. In addition, sera from 35 healthy Swedish and 30 Finnish blood donors were used as controls. Clinical characteristics of the 10 Swedish (11,30,31), 7 Norwegian (12), 12 Italian (5) and 62 Finnish patients (1) with APS I have previously been described. The male/female ratio was 45/46. Vitiligo was present in 3 out of 10 (30%) Swedish, 2 out of 7 (29%) Norwegian, 3 out of 12 (25%) Italian and 11 out of 62 (18%) Finnish patients, thus altogether in 19 out of the 91 (21%) patients. There were 35 males and 58 female patients among the 93 patients with vitiligo not associated to APS I. Thirty-seven of these patients had accompanying autoimmune diseases of which autoimmune thyroid disease was the most prevalent and found in 21 of the patients.
None of these 93 patients had a clinical picture of APS I. 
Preparation of melanocytes.
Human epidermal melanocytes were prepared as described elsewhere (34) . Cells were cultured for 3 weeks in serum free M2 melanocyte medium (PromoCell, Heidelberg, Germany) and were then resuspended in 8% DMSO in fetal calf serum for storage at -150° C until needed (35) .
Western blot. Ten million cells prepared from Caucasian human skin taken during mammary plastic surgery were washed two times in PBS, lysed in loading buffer with 10 mM EDTA and loaded on an SDS-PAGE-gel (36) . Lysates from 5x10 5 cells were loaded in each lane. Western blot was performed as described elsewhere (37) 
Results
Identification of SOX9 as an autoantigen. Four positive clones were identified when the λZAP-cDNA library was screened with serum from one of the Swedish APS I patients with vitiligo.
After in vitro excision of pBK-CMV vectors corresponding to the positive clones, in vitro transcription and translation with T3 polymerase was performed followed by immunoprecipitation with a panel of ten APS I sera. One of the four clones was recognised solely by the serum used for the screening whereas the other three were identified by four of the ten sera.
DNA-sequence analysis revealed that these latter clones all coded for the transcription factor SOX9. Two of the clones were identical with the reported full-length cDNA (38) and one clone represented a truncated SOX9 cDNA. SOX10 is expressed in embryonic melanoblasts (39) and is structurally related to SOX9 with an overall homology of 59 %. This prompted us to assess SOX10 as a possible autoantigen in vitiligo. All APS I patients with immunoreactivity against SOX9 also had reactivity against SOX10. In addition, 6 patients only reacting with SOX10 were identified, three of these having factor (35, 36) . SOX-proteins, and other HMG-box proteins, bind to DNA in a highly sequencespecific manner (40) and are thought to play important roles in the embryonic development of various organs (41, 42) . SOX9 and SOX10 are structurally closely related with almost 100 % homology within a stretch of 110 amino acids and an overall amino acid identity of 59 % (32).
SOX10 is involved in the differentiation of tissues derived from the neural crest and its expression has been detected in the CNS, the PNS, the sympathetic and parasympathetic ganglia and the enteric ganglia throughout the gastrointestinal tract during human embryogenesis. Expression has also been shown in the submandibulary glands, the pancreas, the heart and the lung. In adults, expression of SOX10 has been detected in the brain, prostate, small intestine, colon and heart (43).
Melanocytes are derived from the neural crest and SOX10 expression has been reported in migrating melanoblasts in developing mouse dermis (39) . SOX10 has been shown to bind to the promoter of microphtalmia-associated transcription factor ( We found reactivity against SOX10 in 63% of the APS I patients with, but only in 11% without vitiligo (p<0.0001), indicating a strong association between these autoantibodies and vitiligo. Reactivity against SOX9 was found in a subgroup of the patients with reactivity against SOX10. This may imply cross-reactivity against epitopes shared by SOX9 and SOX10, and that SOX10 is the major autoantigen. This notion is supported by the finding that only in vitro expressed SOX10, but not SOX9, abolished the immunohistochemical staining of melanocytes by APS I sera in preabsorbtion experiments ( Figure 4 ). In addition, in the three patients with vitiligo unrelated to APS I, a strong reactivity was only detected against SOX10.
Unlike SOX10, expression of SOX9 has not been reported in melanocytes. Mutations in the SOX9 gene, causing skeletal malformation syndrome campomelic dysplasia and autosomal sex reversal (female or ambiguous genitalia in individuals with XY genotype)(38,47), have not been associated with pigment abnormalities. Using reverse transcriptase-polymerase chain reaction we were, however, able to detect both SOX9 and SOX10 transcripts in isolated human melanocytes.
Also, using Western blot on lysate from human melanocytes, we identified three bands recognised by sera from 4 out of 8 patients with APS I (Figure 2) . Two of these, the 79 kDa and the 65 kDa bands, corresponded to proteins also detected by the rabbit anti-rat Sox10 antiserum.
Their electrophoretic mobility was lower than that calculated for the molecular weight of SOX10.
We have no explanation for this difference, but similar discrepancies have been described (32) .
The third 45 kDa band was not seen with the specific SOX10 antibody and may represent another melanocyte antigen, yet to be identified. Thus, it is possible that the autoimmune attack against melanocytes in vitiligo may involve both SOX9 and SOX10 as autoantigens, despite findings mentioned above that would support SOX10 as the major autoantigen.
Of the vitiligo patients with APS I 63% also had alopecia areata (p<0.002) and we found that both SOX9 and SOX10 reactivity correlate with this combination of symptoms, whereas no correlation was found with alopecia areata alone. Other studies have found correlations between vitiligo and alopecia areata (18, 48) and antibodies reactive against hair follicle melanocytes (49) and melanoma cell lines (50) in sera from patients with alopecia areata, have been demonstrated using Western blot technique. In our recent study APS I sera also stained melanocyte nuclei in hair follicles (30) . In the present study these sera were shown to be reactive against both SOX9
and SOX10. This indicates that SOX10, and possibly also SOX9, are present in melanocytes in hair follicles, and points to a possible role of melanocytes in the etiology of alopecia areata. Recently, increased frequencies of autoantibodies against SOX13 have been found in sera from patients with type I diabetes mellitus and primary biliary cirrhosis (56, 57) and high-titre autoantibodies against SOX group B transcription factors (SOX1, 2, 3, and 21) were found in sera from 30-40% of patients with small cell lung cancer (58) . This may further indicate important immunogenic properties of this family of transcription factors.
Antimelanocyte autoantibodies have been identified in sera from patients with vitiligo but different frequencies have been reported. Autoantibodies precipitating melanocyte surface proteins were found in 78% of sera from patients with vitligo, compared to only 14 % of the control sera, although only a fraction of the proteins were shown to be melanocyte specific (22) .
The frequency of autoantibodies against the melanocyte specific enzyme tyrosinase, however, ranged from 10% to 60% of sera from patients affected by vitiligo, and even lower frequencies of autoantibodies against TRP-1, TRP-2 and Pmel17 were found (24) (25) (26) 59 ).
In this study we have shown that SOX9 and SOX10 are expressed in human adult skin melanocytes and identified them as autoantigens in APS I. Immunoreactivity against these proteins is associated with vitiligo in APS I. Strong reactivity against SOX10 is also detected in a subgroup of patients with idiopathic vitiligo. The relevance of the serum immunoreactivity against SOX9 and SOX10 for the development of vitiligo in these patients must be further 
